Global Stem Cell Therapy Market was valued at USD 105.24 Million in the year 2017. Global Stem Cell Therapy market is further estimated to grow at a CAGR of 12.33% from 2018 to reach USD 211.39 Million by the year 2023. North America region holds the highest market share in 2017 and the market is also considered as the fastest growing market in the forecasted period. At a country level the U.S. is projected to grow strongly in the coming years. The growth is attributed to the presence of key market players, growing awareness of the stem cell usage in the various application in disorders such as central nervous system disorders, cardiovascular diseases, neurodegenerative diseases, metabolic, eye, and immune system.

Osiris Therapeutics, Inc. (U.S.), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), MEDIPOST Co., Ltd. (South Korea), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) are some of the key players in the Global Stem Cell Therapy market. Organic growth techniques such as expanding global presence along with increasing research and development activities to address the changing demand of the healthcare industry were few techniques adopted by most of the Tier 1 and Tier 2 manufacturers in recent years.
Drivers:
Growing Awareness Related to the Therapeutic Potency and effectiveness for Infection Management
Growing Public-Private Investment models for the Expansion of the Stem Cell Therapies in the developed regions
Restraints:
Varied Regulatory Guidelines across regions pertaining to for new Product Development.
Opportunities:
Government supportive regulations across regions for the usage of stem cell in improving the disease management.
Challenges:
Low Awareness in emerging market due to the Technical Limitations
Stem Cell Therapy market on the basis of various application, the autologous stem cell therapy is further sub categorized into cardiovascular diseases, wounds and injuries, gastrointestinal diseases. The allogenic stem cell therapy segment is estimated to grow at the highest CAGR till 2023. This growth is attributed to the growing usage of the allogeneic stem cell therapy products along with its broad therapeutic uses.

Further, Stem Cell Therapy market when segmented on the basis of source type Bone Marrow and Adipose Tissue both hold substantial market share in 2017. The reason being development of greater genome-based cell investigation methods.

Get Free Report Sample Report with Full Customization https://goo.gl/boZVHP

Key Benefits for Stakeholders
Stem Cell Therapeutic Product Manufacturers, Distributors and Retailers
Research and Development companies
Healthcare service providers like hospitals, laboratories, diagnostic centers
Pharmaceutical companies
Technology Standards Organizations, Forums, Alliances and Associations
Regulatory bodies, Stem Cell Associations and Organizations

By Type
Allogeneic Stem Cell Therapy Market, By Application
Musculoskeletal Disorders
Wounds and Injuries
Surgeries
Acute Graft-Versus-Host Disease (AGVHD)
Autologous Stem Cell Therapy Market, By Application
Wounds and Injuries
Cardiovascular Diseases
Gastrointestinal Diseases

By Cell Source
Adipose Tissue-Derived Mesenchymal Stem Cells
Bone Marrow-Derived Mesenchymal Stem Cells
Cord Blood/Embryonic Stem Cells

By Application
Musculoskeletal Disorders
Wounds and Injuries
Cardiovascular Diseases
Surgeries
Gastrointestinal Diseases

By Region
North America
Europe
Asia-Pacific
RoW

Key Market Players
Medipost Co., Ltd.
Anterogen Co., Ltd.
Pharmicell Co., Ltd.
Holostem Terapie Avanzate Srl
JCR Pharmaceuticals Co., Ltd.
Osiris Therapeutics, Inc.
Nuvasive, Inc.
RTI Surgical, Inc.

Get full Report with TOC https://goo.gl/SCca84

Detailed customization is also available for you. Further, if the report listed above does not meet with your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.